Sensible Biotechnologies
PrivateLast Round
Series A
Oct 5, 2026
Est. Valuation
$1.79M
Total Funding Raised
$60M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Sensible Biotechnologies operates in Healthcare & Life Sciences and is based in Bratislava. Its latest recorded funding round was a Series A round in October 2026.
Sensible Biotechnologies is a biotechnology company that develops a cell-based platform for the design, optimization, and manufacturing of messenger RNA (mRNA).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sensible Biotechnologies Comparables
Compare Sensible Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Waterfall Scientific | 84% | |
| EnPlusOne Biosciences | 82% | |
| NTxBio | 81% |
For institutional investors. Book with your work email.
Sensible Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 5, 2026 | ||||
| Seed Round | Aug 17, 2026 | ||||
| Seed | Apr 9, 2024 | ||||
| Pre Seed | Apr 6, 2023 | ||||
| Accelerator | Aug 31, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sensible Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Slovak Government | Series A |
| Backed VC | Series A, Seed Round, Seed |
| Recode Health Ventures | Pre Seed |
| Recode Health Ventures | Pre Seed, Seed |
| KAYA | Series A, Seed Round, Seed |
| BlueYard Capital | Series A, Seed Round, Seed, Pre Seed |
| Oxford Science Enterprises | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 5, 2026
$47M round led by Oxford Science Enterprises.
- Aug 17, 2026
$14M raised in Seed Round.
For institutional investors. Book with your work email.
Sensible Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sensible Biotechnologies's valuation, stock price, and market status.
Is Sensible Biotechnologies a public or private company?
Sensible Biotechnologies is a private company.
What is the current stock price of Sensible Biotechnologies?
Sensible Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Sensible Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sensible Biotechnologies worth (valuation)?
Sensible Biotechnologies's valuation is estimated at $1.8M based on funding round data.
Can I buy Sensible Biotechnologies stock?
Sensible Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sensible Biotechnologies's last funding round?
Sensible Biotechnologies's most recent funding round was Series A on October 5, 2026.
Who are the main investors in Sensible Biotechnologies?
Key investors in Sensible Biotechnologies include Recode Health Ventures, BlueYard Capital, Oxford Science Enterprises.
Will Sensible Biotechnologies IPO soon?
No public IPO plans have been announced for Sensible Biotechnologies.
How can I track Sensible Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Sensible Biotechnologies's shares on secondary markets.